Singh @NamrataRheum et al. 27,421 RA patients, 8225 on b/tsDMARD. b/tsDMARDs did not increase risk of lymphoma. IR 1.68/1000PY (95% CI 1.5-1.9) on csDMARD vs IR 1.73/1000PY (95%CI 1.4-2.1) on b/tsDMARD. @RheumNow #ACR22 Abstr#1210 https://t.co/3Uvz3mvsGM https://t.co/6k3Vqb21KF

• Use of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs an…

FIND-RA study from Belgium attempts to quantify ILD in early RA. Previously wide ranging estimates 5-20%. They found ILD in 13%. Awaiting full data on ILD severity and progression. @RheumNow ABST1393 #ACR22 https://t.co/ol4iCTkbn9 https://t.co/RLG1ur21dj

• Lung Involvement in Early Rheumatoid Arthritis, Interim Analysis of the FINDRA …

Juge @Juge_P_A @PhilippeDieude et al. RA-ILD patients have shorter telomere length than RA without ILD. RA-ILD similar telomere length to IPF. OR 0.54 for RA-ILD. Assoc with FVC%pred also. @RheumNow #ACR22 Abstr#1122 https://t.co/H5A7unpjjB https://t.co/IjvHmupykM

• Short Peripheral Blood Leukocyte Telomere Length in Rheumatoid Arthritis - Inte…

QD205 - RA Activity During Pregnancy (abstract #0955) #ACR22 28 yoF with active RA during Pregnancy - What are your treatment options? https://t.co/jj99qjugFG https://t.co/vioX8xZw0D

• https://bit.ly/3E0Rfi9

DANBIO registry: 1600+ pts RA, AxSpA, PsA Infiximab biosimilar to biosimilar switch (CT-P13 -> GP1111) Maintenance at 1yr: >80% > withdrawal in original IFX naive, but higher BL DA Do second time switchers do better because of past switch experience? Abs#1112 #ACR22 @RheumNow https://t.co/IgjhGLVESz

Yes. But this only accounts for 1/3 of risk to develop clinical RA. We need a better understanding of the other 2/3 so we can propose efficient preventive interventions. #ACR22 @RheumNow https://t.co/RRzlAISFK3

• https://twitter.com/doctorRBC/status/1591825586401710080

Biosimilar to biosimilar effective in treatment of RA/PsA/AxSpA. Large study looking at infliximab biosimilar switching - resulted in high retention rates and virtually no change in disease activity. @RheumNow #ACR22 Abs#1112 https://t.co/uNRXLewo4M

Most important point from the Great Debate on treating pre-RA. Are we really treating to prevent RA or are we simply delaying RA onset? I don't think there is enough data to treat pre-clinical RA with our current arsenal of DMARDs. What would you do? @RheumNow #ACR22

The Great Debate! Should you treat pre-clinical RA? ACPA+ ~40% did not convert to clinical RA RF+/ACPA+ least likely to seroconvert to negative @RheumNow #ACR22 https://t.co/djVPKDdWjz